FibroGen, Inc (FGEN) Insider K Peony Yu Sells 3,721 Shares

FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 3,721 shares of FibroGen stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $28.95, for a total transaction of $107,722.95. Following the sale, the insider now owns 221,507 shares of the company’s stock, valued at approximately $6,412,627.65. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

K Peony Yu also recently made the following trade(s):

  • On Wednesday, May 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $26.38, for a total transaction of $131,900.00.
  • On Tuesday, April 25th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00.

FibroGen, Inc (NASDAQ FGEN) traded up 1.53% on Friday, reaching $29.80. 822,104 shares of the company traded hands. The firm has a 50 day moving average of $27.85 and a 200-day moving average of $24.85. The stock’s market capitalization is $2.08 billion. FibroGen, Inc has a one year low of $14.50 and a one year high of $29.80.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The business had revenue of $26.89 million during the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. On average, analysts anticipate that FibroGen, Inc will post ($1.81) EPS for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.wkrb13.com/markets/2229034/fibrogen-inc-fgen-insider-k-peony-yu-sells-3721-shares.html.

Separately, Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.50.

Hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. purchased a new stake in FibroGen during the first quarter worth $111,000. Airain ltd purchased a new stake in FibroGen during the first quarter worth $236,000. Parametric Portfolio Associates LLC purchased a new stake in FibroGen during the first quarter worth $249,000. UBS Asset Management Americas Inc. purchased a new stake in FibroGen during the first quarter worth $288,000. Finally, Clinton Group Inc. purchased a new stake in FibroGen during the first quarter worth $297,000. 44.08% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229034/fibrogen-inc-fgen-insider-k-peony-yu-sells-3721-shares.html

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.